.png)
.png)
MDC Connects - Complex Medicines: Understanding the Interplay with Biological Systems
The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs.
What can be learnt from traditional lead optimisation campaigns? Here we consider how to turn a lead in to a molecule with potential to be a medicine.
AGENDA
- The early assessment of prototype nanomedicine nano-bio interactions - Zahra Rattray (University of Strathclyde)
- The interaction of colloidal gene delivery vehicles with model biomembranes - Jayne Lawrence (The University of Manchester)
- The challenges of determining drug levels and PK profiles for complex drug modalities - Robert Wheller (LGC) FREE
What can be learnt from traditional lead optimisation campaigns? Here we consider how to turn a lead in to a molecule with potential to be a medicine.
AGENDA
- The early assessment of prototype nanomedicine nano-bio interactions - Zahra Rattray (University of Strathclyde)
- The interaction of colloidal gene delivery vehicles with model biomembranes - Jayne Lawrence (The University of Manchester)
- The challenges of determining drug levels and PK profiles for complex drug modalities - Robert Wheller (LGC) FREE